ACIU (AC Immune) Tariff Resilience Score: 7/10 (As of Jul. 03, 2026)


ACIU AC Immune SA ACIU
25 GF Score
Price $2.51
GF Value $0.75
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is AC Immune Tariff Resilience Score?

AC Immune ACIU +6.13% 25 Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus rates ACIU with a GF Score™ of 25/100 and a GF Value™ of $0.75 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 1,373 Biotechnology companies, AC Immune ranks better than 90.39% on this metric.

AC Immune has the Tariff Resilience Score of 7, which implies that the company might have Highly Resilient.

AC Immune has AC Immune SA, a biotech firm, has limited exposure to tariffs due to its focus on R&D and licensing rather than manufacturing. Its global partnerships may offer some mitigation, but reliance on international collaborations could pose risks if tariffs impact cross-border research activities.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes AC Immune might have Highly Resilient.

AC Immune  (NAS:ACIU) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

AC Immune Tariff Resilience Score Related Terms

ACIU vs NAUT, IVVD, OTLK: Tariff Resilience Score Comparison

For the Biotechnology subindustry, AC Immune's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

AC Immune Tariff Resilience Score vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, AC Immune's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where AC Immune's Tariff Resilience Score falls into.


ACIU
25GF Score
AC Immune SA ACIU
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 7 mean?
AC Immune (ACIU) has a Tariff Resilience Score of 7 as of Jul. 03, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, AC Immune ranks #132 out of 1373 companies in the Biotechnology industry, placing it in the top 9.6%.
Is AC Immune's Tariff Resilience Score too high?
AC Immune's current Tariff Resilience Score is 7. The Biotechnology industry median Tariff Resilience Score is 4.00. AC Immune's value of 7 is 75% above this industry median. Based on the distribution chart, AC Immune ranks #132 out of 1373 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, AC Immune has a GF Score™ of 25/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does AC Immune's Tariff Resilience Score compare to NAUT and IVVD?
According to the Biotechnology industry distribution chart, AC Immune ranks #132 out of 1373 companies for Tariff Resilience Score. This places AC Immune in the top 10% of its industry — outperforming the majority of peers. The industry median Tariff Resilience Score is 4.00. AC Immune's value of 7 is 75% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Biotechnology company?
The median Tariff Resilience Score among Biotechnology companies is 4.00, based on 1,373 companies in the industry. Companies in the top quartile (top 25%) have a Tariff Resilience Score significantly above this median, while those in the bottom quartile fall well below. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. AC Immune's current Tariff Resilience Score of 7 is 75% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. For the Biotechnology industry, the median Tariff Resilience Score is 4.00 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. AC Immune's current Tariff Resilience Score is 7. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is AC Immune stock overvalued right now?
Based on GuruFocus' analysis, AC Immune (ACIU) is currently considered Significantly Overvalued. The stock's GF Value™ is $0.75, compared to a current price of $2.51 — trading 234.7% above its estimated fair value. The current Tariff Resilience Score is 7 and 75% above the Biotechnology industry median of 4.00. AC Immune's overall GF Score™ is 25/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For AC Immune (ACIU), the current Tariff Resilience Score is 7 as of Jul. 03, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is AC Immune (ACIU) Overvalued in 2026?

Based on GuruFocus' analysis, AC Immune stock appears to be overvalued. The current stock price of $2.51 is trading 234.7% above its estimated GF Value™ of $0.75. GuruFocus considers AC Immune to be Significantly Overvalued.

Key valuation signals for ACIU:

  • Tariff Resilience Score: 7
  • GF Value™: $0.75 vs. price of $2.51 (234.7% above fair value)
  • GF Score™: 25/100 with 6 warning signs
  • Industry Position: 75% above the Biotechnology median (#132 of 1373)

No single metric tells the full story. See the ACIU stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

AC Immune Business Description

Other Exchanges IMR:Germany
Address EPFL Innovation Park, Building B, Lausanne, CHE, 1015
AC Immune SA is a clinical stage biopharmaceutical company advancing a portfolio of programs strategically focused on pioneering Precision Medicine for neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for the prevention, diagnosis, and treatment of neurodegenerative diseases associated with protein misfolding. The company has one segment. The company currently focuses mostly of its resources on discovering and developing therapeutic and diagnostic products targeting misfolded proteins. The company's pipeline consists of ACI-24.060, Crenezumab, ACI-35.030, Semorinemab, ACI-7104.056, and others.
25GF Score

Get the complete analysis for ACIU

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.51
Price
$0.75
GF Value